IPS IPSOS

Ipsos acquires Shanghai Focus RX Research to strengthen its position in pharmaceutical research market in China

Ipsos acquires Shanghai Focus RX Research to strengthen its position in pharmaceutical research market in China

Ipsos acquires Shanghai Focus RX Research

to strengthen its position

in pharmaceutical research market in China

Paris, May 17th, 2023 - Ipsos is pleased to announce the acquisition of Shanghai Focus RX Research. The acquisition will significantly strengthen the expertise of Ipsos China's Pharma Insights business and further support Ipsos' Healthcare Insights business landscape.

The company, established on 2008, is dedicated to the RX (prescription drugs) insight market, including policy and environment research, market expansion, product strategy research, marketing mix research and performance evaluation. Shanghai Focus RX has established a stable and high-quality client base with leading multinational pharmaceutical companies. The company's team of 22 experts will become part of the Ipsos Healthcare Insights business. Frank Ma, CEO and founder of Focus RX Research, will lead the new business team.

Ben Page, CEO of Ipsos, stated: "As outlined during the 2022 Investor Day, the Healthcare sector is one of our main priorities. It is an expanding market in undergoing transformation, and represents a significant growth opportunity for Ipsos. With Shanghai Focus RX Research expertise, we will accelerate and continue the expansion of our core offer and added-value services in a key market in China".

Lifeng Liu, Chairman and CEO of Ipsos in Greater China, says: "Frank Ma is an influential figure in the Chinese RX research market and leads a respected company. I look forward to working with Frank and his team to further strengthen Ipsos' position in the pharmaceutical research market in China".

Frank Ma, CEO and founder of Focus RX Research, adds: "We are delighted to be joining the Ipsos Group. The experienced Focus RX team, armed with Ipsos' global healthcare reach and knowledge, will be able to provide better service and deeper insights to our clients and will certainly make a significant contribution to the development of the healthcare market research in China". 

ABOUT IPSOS

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing nearly 20,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 business solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

“Game Changers” – our tagline – summarizes our ambition to help our 5,000 clients navigate with confidence our rapidly changing world.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).

ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP

Attachment



EN
17/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IPSOS

Ipsos: 1 director

A director at Ipsos bought 500 shares at 37.238EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Cl...

 PRESS RELEASE

Ipsos: Monthly declaration of shares and voting rights - August 2025

Ipsos: Monthly declaration of shares and voting rights - August 2025 September 26, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMF Date   Shares   Voting rights Theoretical* Exercisable** 31 August 2025 43,203,225 48,980,673 48,926,276 *This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation re...

 PRESS RELEASE

Ipsos : Déclaration mensuelle d'actions et de droits de vote - Août 20...

Ipsos : Déclaration mensuelle d'actions et de droits de vote - Août 2025 26 septembre 2025 PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE Articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF Date   Nombre d’actions composant le capital   Nombre total de droits de vote théoriques* exerçables** 31 août 2025 43 203 225 48 980 673 48 926 276 * Ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vot...

 PRESS RELEASE

IPSOS: Monthly declaration of shares and voting rights - July 2025

IPSOS: Monthly declaration of shares and voting rights - July 2025 August 26, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMF Date   Shares   Voting rights Theoretical* Exercisable** 31 July 2025 43,203,225 48,982,585 48,928,856 *This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation ...

 PRESS RELEASE

IPSOS: Déclaration mensuelle d'actions et de droits de vote - Juillet ...

IPSOS: Déclaration mensuelle d'actions et de droits de vote - Juillet 2025 26 août 2025 PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE Articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF Date   Nombre d’actions composant le capital   Nombre total de droits de vote théoriques* exerçables** 31 juillet 2025 43 203 225 48 982 585 48 928 856 * Ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vot...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch